Alnylam Pharmace. buy Evercore ISI
Summary
This prediction is currently active. With a performance of 5.11%, the BUY prediction by Evercore_ISI for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 25.06.25. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | 1.131% | 1.131% |
iShares Core DAX® | -1.611% | 3.135% |
iShares Nasdaq 100 | -0.500% | 0.775% |
iShares Nikkei 225® | -1.483% | 4.610% |
iShares S&P 500 | -0.501% | 1.914% |
Comments by Evercore_ISI for this prediction
In the thread Alnylam Pharmace. diskutieren